Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
It will be the first and only global office for traditional medicine in the world
Routine tests undertaken by women dropped by 35% in 2020
Price was the key driver for the period
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
Subscribe To Our Newsletter & Stay Updated
